Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD","sponsor":"TaiGen Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2.9 million","newsHeadline":"TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD

    Menu

    JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China

              Details:

              Joincare will develop and commercialize TG-1000, a novel pan-influenza antiviral by interrupting viral replication and transmission via a cap-snatching mechanism, revealing efficacy against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses, in china.

              Lead Product(s): TG-1000

              Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: TaiGen Biotechnology

              Deal Size: Undisclosed Upfront Cash: $2.9 million

              Deal Type: Licensing Agreement March 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY